Brian Piekos
CIK 1815308 · Chief Financial Officer · last filed 2026-06-11
Brian Piekos is a Chief Financial Officer who has filed 16 SEC Form 4 insider transactions across 4 companies since 2020. The most recent filing, for KALV, was dated Jun 11, 2026. Across all open-market trades the lifetime net is −$92.7K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KALV price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
55 CAMBRIDGE PARKWAY, SUITE 901E
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Chief Financial Officer | 0 | $27.00 | $0 | -$165.2K | 8 | 2026-06-11 |
| ELTX | Chief Financial Officer | — | $1.57 | — | $0 | 1 | 2024-02-05 |
| Disc Medicine, Inc. (GMTX) Delisted | CFO | 1,762 | $13.50 | $23.8K | $72.4K | 5 | 2022-06-02 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | Chief Financial Officer | 0 | — | — | $0 | 1 | 2020-11-17 |
Recent Filings
16 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-11 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Disp (D) | −21,661 | $0 | EDGAR |
| 2026-05-26 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Mixed | +3,511 | -$39.9K | EDGAR |
| 2026-04-20 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Mixed | +4,388 | -$37.6K | EDGAR |
| 2026-02-24 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Mixed | +3,233 | -$27.5K | EDGAR |
| 2026-01-21 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-11-26 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Mixed | +10,529 | -$60.1K | EDGAR |
| 2025-02-25 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-09-11 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-05 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2023-06-05 | — | Grant (A) | — | $0 |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.